Dr. Ivy Abraham
Hematology & Oncology (Hematology & Oncology Physician)
1740 W Taylor St
Chicago, IL 60612
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 241
Licensed in Illinois since 2017, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036142924 (first issued 2017; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
- Ingalls Memorial Hospital Harvey, IL
Medical groups
- Ucm Medical Group Sub LLC (109 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 241
- Services billed
- 1,308
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 457 | 120 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 130 | 49 |
| Established patient office or other outpatient visit, 20-29 minutes | 106 | 70 |
| Established patient office or other outpatient visit, 40-54 minutes | 101 | 32 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 59 | 34 |
| New patient office or other outpatient visit, 45-59 minutes | 46 | 46 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 43 | 40 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | 21 |
| New patient office or other outpatient visit, 30-44 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Chicago, IL | 211 |
| Eliquis (apixaban) Other prescribers in Chicago, IL | 65 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Chicago, IL | 50 |
| Letrozole Other prescribers in Chicago, IL | 45 |
| Tamoxifen Citrate Other prescribers in Chicago, IL | 37 |
| Dexamethasone Other prescribers in Chicago, IL | 35 |
| Ondansetron Hcl Other prescribers in Chicago, IL | 33 |
| Acyclovir Other prescribers in Chicago, IL | 31 |
| Prochlorperazine Maleate Other prescribers in Chicago, IL | 31 |
| Pomalyst (pomalidomide) | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 27 payments worth $759 in total to this clinician.
| Celgene Corporation | $271 |
|---|---|
| Novartis Pharmaceuticals Corporation | $160 |
| AstraZeneca Pharmaceuticals LP | $102 |
| Daiichi Sankyo Inc. | $54.52 |
| Gilead Sciences, Inc. | $48.20 |
| Array Biopharma Inc | $37.00 |
| Eisai Inc. | $36.15 |
| Blueprint Medicines Corporation | $19.93 |
| Food and Beverage | $759 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $23,907 in research payments for these studies, mostly to the institutions running them.
- Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors
Pfizer Inc. - An open-label, multicenter, long-term treatment extension study in sub
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.